

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10572974
Filing Date	2006-03-02
First Named Inventor	Jones et al.
Art Unit	1614
Examiner Name	A. Pagonakis
Attorney Docket Number	PR60397USw

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5300300	A	1994-04-05	Egidio Marchi et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	03/090745	WO	A	2003-11-06	Klewer Steven Anthony, Wilson Tim/Smithkline Bee		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10572974		
Filing Date	2006-03-02		
First Named Inventor	Jones et al.		
Art Unit	1614		
Examiner Name	A. Pagonakis		
Attorney Docket Number	PR60397USw		

1	LIU YAPING ET AL.; The protective effect of GW4064 on bile duct ligation-induced hepatotoxicity in rats: Role of activated FXR; Hepatology; October 2002; 36/4 part 2; 339A;	<input type="checkbox"/>
2	LIU Y ET AL.; The protective effect of GW4064X on alpha-naphthylisothiocyanate (ANIT)-induced hepatotoxicity in mice: Role of activated FXR; Toxicological Sciences; March 2003; 72/no. S-1; 371;	<input type="checkbox"/>
3	MALONEY P.R. ET AL.; Identification of a chemical tool for the orphan nuclear receptor FXR; Journal of Medicinal Chemistry; 10 August 2000; 43/16; 2971-2974;	<input type="checkbox"/>
4	PELLICCIARI R ET AL.; 6.alpha.-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity; J. of Med. Chem; 20 July 2002; 45/17; 3569-3572; American Chemical Society; Washington DC	<input type="checkbox"/>
5	MURPHY F ET AL.; Developing strategies for liver fibrosis treatment; Expert opinion on investigational drugs; 1 November 2002; 11/11; 1575-1585;	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.